Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances Wages, Salaries and Other

Journey Medical (DERM) Short-Term Debt repayments (2021 - 2023)

Journey Medical filings provide 3 years of Short-Term Debt repayments readings, the most recent being $3.0 million for Q2 2023.

On a quarterly basis, Short-Term Debt repayments changed N/A to $3.0 million in Q2 2023 year-over-year; TTM through Dec 2023 was $30.9 million, a 980.59% increase, with the full-year FY2023 number at $30.9 million, up 980.59% from a year prior.
Short-Term Debt repayments hit $3.0 million in Q2 2023 for Journey Medical, down from $27.9 million in the prior quarter.
In the past five years, Short-Term Debt repayments ranged from a high of $27.9 million in Q1 2023 to a low of $812000.0 in Q1 2022.
Median Short-Term Debt repayments over the past 3 years was $2.1 million (2022), compared with a mean of $6.9 million.
Biggest five-year swings in Short-Term Debt repayments: soared 131.08% in 2022 and later soared 3341.87% in 2023.
Journey Medical's Short-Term Debt repayments stood at $888000.0 in 2021, then surged by 131.08% to $2.1 million in 2022, then soared by 46.2% to $3.0 million in 2023.
The last three reported values for Short-Term Debt repayments were $3.0 million (Q2 2023), $27.9 million (Q1 2023), and $2.1 million (Q4 2022) per Business Quant data.